Since the publication of the last US national burden of skin disease report in 2006, there have been substantial changes in the practice of dermatology and the US health care system. These include the development of new treatment modalities, marked increases in the cost of medications, increasingly complex payer rules and regulations, and an aging of the US population. Recognizing the need for up-todate data to inform researchers, policy makers, public stakeholders, and health care providers about the impact of skin disease on patients and US society, the American Academy of Dermatology produced a new national burden of skin disease report. Using 2013 claims data from private and governmental insurance providers, this report analyzed the prevalence, cost, and mortality attributable to 24 skin disease categories in the US population. In this first of 3 articles, the presented data demonstrate that nearly 85 million Americans were seen by a physician for at least 1 skin disease in 2013. This led to an estimated direct health care cost of $75 billion and an indirect lost opportunity cost of $11 billion. Further, mortality was noted in half of the 24 skin disease categories. ( J Am Acad Dermatol 2017;76:958-72.)
S
kin disease is one of the leading causes of global disease burden, affecting millions of people worldwide. 1 Aging, environmental and genetic factors, and trauma can result in the development of a diverse set of skin diseases, with over 3000 entities identified in the literature. 2, 3 A limited number of studies have addressed the burden of skin disease (BSD) in the United States. [4] [5] [6] The most comprehensive study was a 2006 publication by the American Academy of Dermatology (AAD) and the Society for Investigative Dermatology (SID), based on data before 2004. 4 Since 2006, there have been substantial changes in the practice of dermatology and in the US health care system. These changes include the development of new treatment modalities, marked increases in the cost of medications, increasingly complex payer rules and regulations, and an aging US population. In response to these changes, the AAD developed this updated national BSD report to provide a comprehensive appraisal of skin disease prevalence, mortality, and current direct health care and indirect economic costs. This report analyzed information from the 2013 claims tabulations of the US population pertaining to 24 skin disease categories that broadly represent skin diseases relevant to both the practice of dermatology (medical, surgical, and pediatric) and to other health care providers treating the skin. Therefore, in this report, data are presented for patients with skin disease treated by dermatologists and/or by other physicians who are not dermatologists.
METHODS
In 2014, the AAD appointed a BSD Work Group* to develop a current BSD report. Milliman (New York, NY) was selected to work with the BSD Work Group. Detailed methodology can be found in the AAD BSD report. 5 
Skin disease categories
The work group identified 24 skin disease categories for inclusion in this report, and assigned the appropriate corresponding International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes, which were in use in 2013. The following principles for identifying and assigning ICD-9 codes were established: d Diseases of hair, nails, lips, eyelids, external genitalia, and external ear were included as skin disease. d Skin damage from external causes (eg, thermal burns) and cutaneous manifestations of systemic diseases (eg, drug eruptions from chemotherapy) were included. d Skin diseases that overlapped 2 or more categories were assigned to the most prevalent one (eg, eczema not otherwise specified was assigned to dermatitis not otherwise specified; ICD-9 692.9).
It should be noted that diagnosis codes pertaining to diseases that are remotely or rarely associated with skin manifestations were not included in this analysis; these included bone/skin neoplasms and other nonclassifiable diagnoses such as unspecified disorder of skin and subcutaneous tissue (ICD-9 709.9). Table I shows the skin diseases assigned to the 24 categories. The list of ICD-9 diagnoses for each category can be accessed in the full report. 5 
US population and insurance classifications
Medical 6, 7 A set of data selection rules for each database source was established to ensure representative and quality data. 5 
Prevalence measurement methodology
Prevalence in this report refers to the portion of the population having the diagnosis of at least 1 of the 24 skin disease categories recorded on a health insurance claim during the course of 2013. A skin disease diagnosis during 2013 may reflect both newly diagnosed skin disease and chronic skin disease requiring ongoing treatment (eg, acne, psoriasis). Prevalence by disease category was calculated as the number of single-counted individuals with a diagnosis in the category divided by the total population. This approach to prevalence, therefore, excludes people with skin disease who did not file insurance claims (ie, did not see a physician), regardless of reason, during 2013 (Fig 1) . For the uninsured population, prevalence was estimated using the Medicaid population, adjusting for the CAPSULE SUMMARY The costs and prevalence of skin disease are comparable with or exceed other diseases with significant public health concerns, such as cardiovascular disease and diabetes.
age mix from Medical Expenditure Panel Survey population data.
Health care costs
Skin disease claims were identified using diagnosis codes, procedure codes, national drug codes, and physician specialty identifiers to select skin diseaseeassociated claims. When a claim had diagnoses for skin and nonskin diseases, costs were divided among the conditions such that only the skin disease portion was included in tabulations.
Health care costs definitions. Costs are for services and prescription drugs typically paid for by commercial, Medicare, and Medicaid health insurance plans. Costs do not include long-term nursing home and community services and supports. Costs are the sum of the total cost paid by the insurance plan(s) and patient cost sharing (allowed costs). Patient cost sharing includes deductibles, coinsurance, and copayments. Costs were not reduced to reflect prescription drug rebates paid to insurance plans or to pharmacy benefit managers by drug companies.
Medical (nondrug) costs. For category 1 claims, a skin percentage was assigned based on a formula that weights the total number and position of skin disease diagnoses on the claim. Medical services and costs identified in categories 2 to 4 were assigned 100% to skin disease. Services and costs for the 24 skin disease categories were assigned to the first skin diagnosis on the claim. Medical costs from claims were tabulated on various aspects of health care services, including inpatient services, outpatient therapies, emergency room and observation visits, surgeries, nonsurgical dermatology procedures (eg, phototherapy), office visits, and vaccines. For the uninsured population, commercial tabulated costs were used and the uninsured to commercial cost ratio by type of service was applied.
Prescription drug costs. Table I ; available at http://www.jaad.org).
Drug use and costs identified in categories 1 and 2 were assigned 100% to skin disease. A skin percentage value of less than 100% that took into account the overall cost for each drug, and the percentage of prescriptions issued by specialty or nonspecialty providers, was assigned to drugs identified in category 3. The identified prescription drugs and costs were tabulated by insurance status, type of drug, specialty status, and therapeutic class.
OTC products. OTC product costs were identified using 2013 US OTC product retail sales estimates from Information Resources Inc (Chicago, IL), which collects cash register scanner data from US drug stores, grocery stores, and mass merchandisers to produce national estimates of consumer purchases. Because skin-related OTC products may include cosmetic and other nondisease-oriented products, only product categories intended to help in the management of skin diseases were analyzed. In all, 22 OTC products categories were identified as related to skin care, such as sunscreens or antihistamines (Supplemental Table II ; available at http://www.jaad.org).
Indirect costs
Opportunity costs. Total patient-days of interaction with the health care system were calculated as Abbreviations used:
American Academy of Dermatology BSD:
burden of skin disease CDC:
Centers for Disease Control and Prevention ICD-9: International Classification of Diseases, Ninth Revision OTC:
over-the-counter SID:
Society for Investigative Dermatology YPLL: years of potential life lost the product of the number of services and estimated interaction time. Full and partial day patient-time estimates were assigned to claims by the type of service (eg, inpatient, outpatient, office visit). If a claim had more than 1 procedure for the same type of service (eg, 2 surgery procedures) on the same day, patient-days of interaction were assigned to only 1 procedure. Similarly, the number of services included only the skin percentage portion of services as described previously. Patient-days of interaction were converted to opportunity cost using the 2013 average hourly wage data from the Bureau of Labor Statistics. Although not everyone is employed, everyone has an opportunity cost, and average wages are used as a proxy for that metric. For children, the opportunity cost was calculated as the parents' opportunity cost. The 2013 average hourly wage was $23.97, or $191.76 per 8-hour day. 8 Literature searches. A search was conducted to identify peer-reviewed articles and government reports describing the indirect cost BSD, other than mortality and patient-time, for the US population. PubMed and Google Scholar were used to identify English-language literature meeting the inclusion criteria indicated below: Data from clinical trials were excluded, as these studies select specific affected populations.
Mortality from skin disease
Data corresponding to 2013 deaths-by-cause from the Centers for Disease Control and Prevention (CDC) Wide-ranging Online Data for Epidemiologic Research System were used to determine the number of deaths as a result of skin disease in 2013. The CDC records causes of death using 4-digit International Statistical Classification of Diseases, 10th Revision codes. Skin diseases were mapped between the ICD-9 codes used in the claims analysis to the International Statistical Classification of Diseases, 10th Revision codes using the General Equivalence Mappings provided by the Centers for Medicare and Medicaid Services.
A well-accepted statistical method to estimate premature mortality as a result of a specific condition is to calculate years of potential life lost (YPLL). YPLL complements absolute number of mortality data, and takes into account the age at which deaths occur by giving greater weight to deaths at younger age and lower weight to deaths at older age. 9, 10 It is an estimation of the average years that a person would have lived had he/she not died prematurely; it is a measurement of premature mortality. 11 Total YPLL was calculated for each skin disease by using 75 years as the reference age. Therefore, a person who died at 50 years of age would have a YPLL of 25 (=75, minus 50), whereas a person who died at 80 years of age would have a YPLL of 0 (age of death being greater than the reference age of 75 years).
RESULTS
US claims-based prevalence of skin disease in 2013 Nearly 85 million Americans (27% of population; 1 in 4 individuals) were seen by a physician for skin disease in 2013 (Fig 2, A) . Overall, affected individuals averaged 1.6 skin diseases. Up to 64 years of age, the prevalence and average number of skin diseases per person was relatively similar for all age groups; however, the prevalence increased to nearly 50% for those age 65 years and older, with an average of 2.2 skin diseases diagnosed per person (Fig 2, B) . Comparable prevalence and average number of skin diseases were observed for all age groups across the commercial, Medicaid, and uninsured populations (Fig 2, C ) . In contrast, for Medicare population, the prevalence of skin disease was 34% in the age group 18 to 44 years; the prevalence increased to 49.4% for those age 65 years and older, with a corresponding increase in the average number of skin diseases to 2.3. However, it should be noted that the group age 65 years and older only represents less than 1% of the commercial population.
Skin disease prevalence for the total population ranged widely across all 24 categories. Prevalence was highest for the categories of noncancerous skin growths (defined as benign neoplasms/keloids/ scars/cysts), cutaneous infections and viral and fungal diseases, wounds and burns, contact dermatitis, and actinic damage. Prevalence was lowest for bullous diseases, cutaneous lymphoma, and vitiligo (Fig 3) .
Direct US health care costs of skin disease
The total estimated direct cost of skin disease in 2013 was nearly $75 billion (Fig 4, A) . Of this total cost, $46 billion was attributable to medical costs (office visits, procedures, tests), $15 billion to prescription drugs, and $4 billion to vaccines (;58%), other skin procedures (;42%), and skin cancer screening (\0.1%). The total of these 3 categories of $65 billion corresponded to 3.8% of 2013 total US health care costs. Cost corresponding to OTC products for skin disease was nearly $10 billion.
Across skin disease categories, estimated medical costs ranged from over $8 billion for cutaneous infections to $49 million for vitiligo (Fig 4, B) . The medical costs of the 10 skin disease categories with of skin disease by age and insurance status in the US population. A, Graphic representation of the percentage of the US population with any skin disease (tan shading). B, The stacked column graph shows the relative US population with (pink) and without (blue) skin disease by age group. The prevalence for any skin disease (pink columns) is indicated as percentage, actual number of individuals (in millions), and the average number of skin diseases if any within parentheses. C, The pie charts represent the percentage of total US population by insurance status (commercial, Medicare, Medicaid, and uninsured), age group, and percentage of individuals affected with skin disease. The labels for each pie slice (age group) indicate the actual number of individuals (in millions), prevalence of skin disease (percentage; in bold), and the average number of skin disease (in parentheses).
the largest economic burden (ie, from cutaneous infections to connective tissue disease) (Fig 4, B) totaled nearly $40 billion, constituting over 85% of the estimated total medical costs for all skin disease. The relative cost/prevalence ratio for each skin disease varied across the 24 skin disease categories. Cutaneous lymphoma, ulcers, and melanoma had high cost relative to their prevalence. Conversely, atopic dermatitis, pruritus, and seborrheic dermatitis had a lower cost relative to their prevalence (Fig 5) .
Skin disease drug and vaccine costs
Of the $15.6 billion for skin disease prescription drugs and vaccines covered by insurance in 2013, nonspecialty drugs (typically nonbiologic, long established drugs) 12 accounted for the majority of these costs (72%), whereas specialty drugs (typically biologic and/or injectable drugs) 12 and vaccines each accounted for 15% and 13% of the total, respectively (Fig 6, A) .
As shown in Fig 6, B , the highest total sales of dermatology-related OTC products included acne treatments, body and facial antiaging products, depilatories, facial cleansers and moisturizers, fade/ bleach products (eg, skin care category), hand and body lotion, first-aid treatments, and sunscreen. Dividing total US OTC sales costs by the total US population results in a 2013 OTC cost per capita of $31.91.
Cost of skin disease per capita
Dividing the total skin disease health care costs of $75 billion in 2013 by the total US population results in a cost of skin disease per capita of nearly $240 (Fig 7) . The average cost per person affected with skin disease was $887 (data not shown). Of the $240 per US capita, medical costs accounted for 61%, whereas 20% was for prescription drugs, 6% was for screening/vaccines/others, and 13% was for OTC products (Fig 7, left) . The specific medical cost per capita for each of the 24 skin disease categories is shown in Fig 7, right. In general, skin diseases with high prevalence also had high medical costs per capita.
Comparison of the cost of skin disease between 2004 and 2013
The 2006 AAD/SID BSD report, 4 which used data before 2004, estimated the total health care costs of skin disease at approximately $29 billion. This current report, using claims data for 2013, estimates it to be nearly $75 billion (Table II) . It should be emphasized that these 2 reports use different methodologies and have variations in the skin disease categories analyzed, making direct dollar comparisons difficult. With these limitations in mind, adjusting the 2004 estimated cost for inflation 13 to 2013 US$ ($29 billion, to $44 billion), shows an increase in the BSD of 1.7-fold (Table II) .
Skin disease opportunity cost
Having skin disease affects work and life productivity, both for patients and their caregivers. The 2013 estimated opportunity cost for skin disease approached $11 billion (Fig 8) . In general, the skin diseases with the highest prevalence also had the highest opportunity costs, although their relative position among the 24 studied diseases varied. Cutaneous infections, noncancerous skin growths, wounds and burns, and viral and fungal diseases led the list of skin diseases with opportunity costs nearing or exceeding $1 billion.
Impact of skin disease on US life expectancy
Skin disease directly caused 22,953 deaths (0.9% of the total number of deaths) in 2013 (Fig 9, A) . On average, death from skin disease occurred at age 68.2 years, 5 years younger than the average age of death (for all causes) during 2013. One half of the 24 skin disease categories had deaths associated in 2013. Skin cancer (melanoma, nonmelanoma, and cutaneous lymphoma) accounted for over 60% of all skin disease-related deaths. Melanoma accounted for the most skin diseaseerelated deaths (41%). Wounds and burns (15%) and cutaneous infections (10%) had the highest number of skin disease deaths not related to skin cancer (Fig 9, B) .
Fatal skin disease leads to mortality at younger ages compared with other causes of death. Assuming a potential life expectancy of 75 years, the YPLL as a result of fatal skin disease was nearly 11, 2.9 years greater than the YPLL for all causes of death.
Other indirect costs attributable to skin disease
Only 2 governmental reports and 2 published articles (both analyzed non-US populations) were identified that provided population-level, multiskin disease indirect cost assessments.
14-17 Although extensive literature was noted on the indirect BSD, it was most often associated with a specific disease, and further limited to a specific subset of the population with the disease, precluding a cohesive multidisease assessment of the indirect costs of skin disease. Examples of the single-disease literature are shown in the full report.
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DISCUSSION
The last AAD/SID US BSD report was developed using data that are now more than 12 years old. Since then, the national health care landscape has rapidly and significantly changed. [38] [39] [40] These changes include the Affordable Care Act, Medicare Access and Children's Health Insurance Program Reauthorization Act of 2015, evolving US demographic trends, a vast array of new drugs and treatment options, and new technologies to facilitate remote diagnosis and treatment. [38] [39] [40] [41] [42] The number of Americans that were seen by a physician for some form of skin disease in 2013 was nearly 85 million, slightly over one quarter of the entire US population. This combined prevalence exceeds current annual estimates for all cardiovascular diseases and diabetes, [43] [44] [45] making skin disease an important public health consideration. The analysis used in this report reflected only the economic burden for those who received care and had medical claims made in 2013, therefore, these calculations likely underestimate the true population burden and the prevalence of disease in the population. For instance, this report estimates the prevalence of psoriasis to be 0.5% and vitiligo to be 0.05%, whereas other studies estimate the population prevalence to be 2.2% to 4.7% and 0.5% to 2%, respectively. [46] [47] [48] [49] Despite the limitations of claimsbased prevalence, this approach resulted in a consistent calculation and cross-comparison of results across all 24 skin disease categories for the US population.
Importantly, those seen with skin disease tended to have more than 1 skin disease during the year, averaging 1.6 skin diseases. This average increased to 2.2 skin diseases for individuals 65 years and older, indicating a trend of more skin disease with age. Although skin disease in general infrequently caused death, it is noteworthy that 12 of the 24 skin disease categories had associated deaths in 2013. Skin cancers (melanoma, nonmelanoma, and cutaneous lymphoma) resulted in over 60% of all skin-related deaths in 2013. This finding underscores the importance of early detection and treatment.
Many skin diseases in the population aged 65 years old and older are related to lifelong cumulative sun exposure (eg, actinic damage and skin cancer), and increasing susceptibility to bacterial, viral, and fungal diseases. By 2030, the US population aged 65 years and older is estimated to grow by 30 million individuals, and to steadily increase through 2050, with a projected total population aged 65 years and older of 85 million. 50 Growth in national health expenditures is projected to double between 2013 and 2020. 42 With the physician workforce projected to remain relatively flat, the specific ratio of dermatologists to population will decrease over time, especially in rural areas. 51 These projections indicate a current and future challenge to ensure patient access to appropriate dermatologic care.
51-53 The cost for individual skin diseases varied widely, partially because of differences in prevalence, but also because of the cost of medical and surgical treatment options. Distributed across the entire US population, the total 2013 health care cost of skin disease was approximately $240 per capita. Other diseases, such as cardiovascular disease, diabetes, and end-stage renal disease have significantly higher direct and per affected person costs than skin disease. 43, 44, [54] [55] [56] [57] However, the per capita costs for these 3 diseases are, similar to skin disease, less than $1000 (ie, $950 for cardiovascular disease, $785 for diabetes, and $147 for end-stage renal disease).
Although there are limitations on direct comparison of the previous AAD/SID BSD report and this current report, it reveals that from 2004 to 2013 there has been a roughly 1.7-fold increase in skin disease health care costs. Of note, many new and more effective drugs and treatment options for skin disease were introduced between 2004 and 2013, albeit at higher costs than older treatments. Examples include new topical medications for acne, biologics and excimer laser for psoriasis, checkpoint inhibitors for melanoma, and oral and systemic treatments for cutaneous lymphoma. 49, [58] [59] [60] [61] [62] Since 2013, costs of many widely used dermatologic medications have increased significantly, and better understanding of the pathophysiology of diseases has led to development of new medications. Therefore, the health care cost of skin disease at the time of writing this article most likely surpasses this 2013 estimation.
This report estimates that the 2013 opportunity cost as a result of skin disease was nearly $11 billion. Similar to the prevalence and economic BSD, it is also likely that the opportunity cost may be underestimated, as these estimates are calculated using claims-based methods. Although it is well recognized that skin diseases can inflict an enormous toll on the physical and psychosocial well-being of patients and their families, [63] [64] [65] there is currently a lack of adequate studies on quality-of-life measures to systematically estimate the costs on a population level across all skin diseases.
There are limitations to this study. The use of 2013 claims-based prevalence provides a snapshot in time of the actual health care landscape; however, it does underestimate the true prevalence of the disease, as it only accounted those who filed insurance claims in 2013. Furthermore, it limits direct comparisons with other reports that use differing assessments of prevalence and disease costs. The health care landscape has rapidly evolved since 2013; therefore, the true burden at the time of this writing is most likely higher.
In summary, this article presents an up-to-date US national BSD report that addresses 24 skin disease categories. Skin disease is a significant and serious public health consideration for the US population, costing at least $75 billion to treat in a single year. Although this study's approach likely underestimates overall burden, it ensures consistency in comparing prevalence, economic, and mortality data across the 24 skin disease categories. With the projected increase in the age group 65 years and older in the US population, combined with the increased costs of currently in-use and newly developed dermatologic treatment options, the economic BSD will continue to grow. The increased number of individuals older than 65 years, who have higher skin disease burden, needs to be addressed by an appropriate increase in dermatologic care providers. We also thank any other not listed here who contributed to the development and success of this report. 
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